
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is positioned for continued growth with an expanding product and service offerings, strategic initiatives, and a strong portfolio. However, competition and developing new diagnostic solutions may pose challenges in the future. The company has seen positive financial results for Q2, with increased revenue and EBITDA guidance, as well as growth in testing volume and strategic acquisitions and divestitures.
Bears say
CareDx is facing significant financial stress due to the limitations imposed by Medicare, resulting in a drastically reduced total addressable market for its testing services. Additionally, its expansion into the MRD and oncology diagnostics market may not be enough to offset the loss of revenue and stabilize the company's financial performance. However, limited competition in the market may provide some protection for CareDx in the short term, but investors should keep a close eye on Natera as a potential competitor in the future.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares